The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
Tenaris SA ADR
TS · the NYSE · USD · Market cap $29.7B · 24,875 employees
Tenaris S.A., together with its subsidiaries, manufactures and supplies steel pipe products and related services for the energy industry and other industrial applications in North America, South America, Europe, the Midd…
PASS · Titan Ethical · score 70.0Price as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price57.50 USD at the 19 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 17 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.25)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $37.80 to $58.21, base estimate $50.61 (screen dated 2026-11-19).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.25, read 2026-11-19
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Tenaris SA ADR holds its Markup at $57.50. Consolidating, no directional conviction, held for 387 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 387 days |
| Price at the screen | $57.50 |
| Valuation | 15.09 trailing · 14.02 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.43 |
Five Screens: TS's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 2.24% | Below 33% | Pass |
| Interest-bearing cash | 11.49% | Below 33% | Pass |
| Receivables | 12.42% | Below 49% | Pass |
| Revenue purity | 1.91% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
Tenaris clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 2%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TS's ethical verdict changes
Today TS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 19 Nov 2026: it trades above our $50.61 fair value estimate, narrow competitive moat, 4.20% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 13.6% above the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $50.61, with a range of $37.80 to $58.21, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain WordsOil pipe maker looks cheap but cycle warns
Oil drillers ramp up pipe orders in booms then slash them the moment prices dip. Tenaris supplies those pipes yet sits above our fair value with a negative margin of safety, so we pass despite the 14 times forward earnings and ethical screen clearance.
Revenue is rising only 6 percent while profit margins sit at 16 percent and return on equity at 12 percent. The narrow moat and buy-rated analyst target of 64 dollars cannot hide that this is a cyclical business where a low multiple often signals peak earnings rather than a bargain.
Currency swings, oil price shocks and regional demand drops remain real threats that could compress those margins quickly. Analysis, not advice.
| Forward P/E | 14.0xexpensive even after accounting for its growth |
| Trailing P/E | 15.1xreasonably valued |
| EPS, trailing | 3.90 |
| EPS, forward | 4.20 |
| Revenue growth | +4.2%slow but positive growth |
| Profit margin | 16.2%healthy profit margins |
| Return on equity | 11.9%a modest return on shareholder capital |
| FCF yield | 6.49% |
| Dividend yield | 3.11% |
| Debt to equity | 2.83heavy leverage: higher risk if revenue softens |
| Current ratio | 3.25comfortably covers its short-term bills |
| Beta | 0.43barely tracks the market's swings |
| Short interest, float | 0.02% |
| 52-week range | 37.69 - 64.60 |
| Moat | NARROW |
| Market cap | $29.7B |
| Employees | 24,875 |
TS-specific watchpoints · The things to watch: its business and earnings are exposed to Luxembourg and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (12 analysts) rates it none, with a mean price target of $64.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Best Momentum Stocks to Buy for November 11th Yahoo Finance · 9d ago
- New Strong Buy Stocks for November 11th Yahoo Finance · 9d ago
- Best Income Stocks to Buy for November 11th Yahoo Finance · 9d ago
- What Tenaris (TS) Said on Its Q3 Earnings Call Yahoo Finance · 12d ago
- Tenaris SA (TS) Q3 2026 Earnings Call Highlights: Strong Sales Growth, 24% EBITDA Margin, and a ... Yahoo Finance · 14d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-11-03 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-22 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-22 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-20 | Bob Latta | Republican | buy | 1K–15K |
| 2026-10-20 | Bob Latta | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $58.41 | -1.5% | · | $985 | -1.5% |
| 2 months | $56.25 | +2.2% | · | $1,022 | +2.2% |
| 3 months | $52.68 | +9.2% | · | $1,092 | +9.2% |
| 6 months | $61.61 | -6.7% | · | $934 | -6.7% |
| 1 year | $39.53 | +45.5% | $1.20 | $1,485 | +48.5% |
| 2 years | $35.06 | +64.1% | $2.86 | $1,722 | +72.2% |
| 3 years | $30.97 | +85.7% | $4.06 | $1,988 | +98.8% |
| 5 years | $18.06 | +218.4% | $5.90 | $3,510 | +251.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.